This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.

AGILE: Seamless Phase I/IIa Platform for the Rapid Evaluation of Candidates for COVID-19 treatment [COVID-19] [UPH]

  • Research type

    Research Study

  • Full title

    Agile - Seamless Phase I/IIa Platform for the Rapid Evaluation of Candidates for COVID-19 treatment (not AGILE-ACCORD: ACcelerating COVID-19 dRug Development - Phase I/II trial platform. A Randomized, Multicentre, Seamless, Adaptive Phase I/II Platform Study to Determine the Optimal Dose, Safety and Efficacy of Multiple Candidate Agents for the Treatment of COVID-19 – that is the old name, all protocols and documents have been updated to Agile)

  • IRAS ID

    282781

  • Contact name

    Saye Khoo

  • Contact email

    khoo@liverpool.ac.uk

  • Eudract number

    2020-001860-27

  • ISRCTN Number

    ISRCTN27106947

  • Duration of Study in the UK

    1 years, 6 months, 0 days

  • Research summary

    In late 2019 a novel coronavirus-induced disease (COVID-19) emerged in humans in Wuhan, China (SARS-CoV-2) which is now a pandemic. Of those who are admitted to hospital most get better, but some may need oxygen or mechanical ventilation before they do so, and a small number do not get better and die. The virus is highly contagious and is causing an enormous strain on NHS resources. There are currently no approved drugs to treat COVID-19. There are currently late phase platform trials looking at repurposing existing drugs (e.g. RECOVERY) but there are a lack of trials investigating new treatments.\n\nThe AGILE-ACCORD phase 1/2 platform master protocol allows incorporation of new potential treatments (candidates) that either only have laboratory data or limited patient data to indicate they may work to treat COVID-19. This early phase platform will look closely at dose, safety and evidence that they work before entering these other large phase trials.\n\nCandidates will be added into the trial (at varying times) via candidate-specific trial protocols of a master protocol. Patients will be randomised between candidate and control with 2:1 allocation in favour of the candidate. Each dose will be assessed for safety sequentially in cohorts of 6 patients, with more patients receiving the optimal dose to assess efficacy and safety. The patient population for this trial is adult patients (≥18 years) who have laboratory-confirmed infection with SARS-CoV-2. It will include both severe and mild-moderate patients. Each candidate-specific trials are expected to recruit ~40 patients.

  • REC name

    West Midlands - Edgbaston Research Ethics Committee

  • REC reference

    20/WM/0136

  • Date of REC Opinion

    12 May 2020

  • REC opinion

    Further Information Favourable Opinion